Anti-inflammatory agent 89
Anti-inflammatory agent 89 is a multi-target glucocorticoid-isothiocyanate hybrid with anti-inflammatory activity. Anti-inflammatory agent 89 releases hydrogen sulfide via its isothiocyanate group, inhibits antigen-induced mast cell degranulation, alleviates pulmonary inflammation, and suppresses bronchial hyperresponsiveness and airway fibrosis. Anti-inflammatory agent 89 can be used in asthma research.
For research use only. We do not sell to patients.
- Formula: C31H39NO7S
- Molecular Weight:569.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
IL-13 |
Anti-inflammatory agent 89 (compound 5c) (200 μM; up to 4 h) shows moderate enzymatic stability in BSA medium, with a half-life of 1.4 h, and releases its parent glucocorticoid upon metabolism[1].
Anti-inflammatory agent 89 acts as a slow, sustained H2S donor in a cell-free environment[1].
Anti-inflammatory agent 89 (100 μM; 24 h) is non-cytotoxic to RBL-2H3 mast cells[1].
Anti-inflammatory agent 89 (100 μM; 5 min prior to 1 h degranulation stimulus) potently inhibits antigen-induced degranulation of RBL-2H3 mast cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RBL-2H3 mast cells
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Did not reduce cell viability compared to the vehicle.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 8 weeks old, 20 g, ovalbumin-induced asthma model)[1]
-
Dosage:1 mg/kg; 2 mg/kg
-
Administration:i.p.; 2 doses (30 minutes before ovalbumin sensitization on days 0 and 7)
-
Result:Mitigated carbachol-induced bronchial hyperreactivity at 1 mg/kg, without complete recovery of pulmonary architecture or elimination of lung inflammation.
Normalized bronchial reactivity to baseline values at 2 mg/kg.
Lessened α-SMA-positive muscular layer thickness at 2 mg/kg, indicating alleviated airway fibrosis.
Recovered intact lung structure at 2 mg/kg via eliminating cellular infiltration, smooth muscle hyperplasia and lamina propria detachment.
Lowered plasma IgE concentrations markedly at 2 mg/kg.
Diminished pulmonary IL-13 contents in a dose-responsive fashion.
Chemical Information
-
Molecular Weight 569.71
-
Formula C31H39NO7S
-
SMILES
O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])C[C@@H]5[C@@]4(C(COC(CSC#N)=O)=O)O[C@]([H])(C6CCCCC6)O5)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-inflammatory agent 89 Related Classifications
HY-161815 Related Classifications
Powered by Bioz